AveXis is a clinical-stage gene therapy company developing innovative treatments for rare and life-threatening genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
AveXis is a rapidly growing leader among gene therapy biotech companies and continues to establish relationships with academics, biotechnology and pharmaceutical companies, and healthcare investors.
|Boxer Capital, RTW Investments, T. Rowe Pricewdxefcqufszuzezftuxetqsqxt, Roche Venture Fund, Foresite Capital, RA Capital Management, Deerfield Capital Management, Janus Capital Group, Rock Springs Capital, Adage Capital Management, Venrock, Deerfield, QVT Financial|
AveXis has 903 Twitter Followers. The number of followers has increased 2.2% month over month and increased 11.3% quarter over quarter
When was AveXis founded?
AveXis was founded in 2010.
Who are AveXis key executives?
AveXis's key executives are Sean Nolan, Phillip Donenberg and Sukumar Nagendran.
Who are AveXis competitors?
Competitors of AveXis include Viacord, Idera Pharmaceuticals and Akebia Therapeutics.
Where is AveXis headquarters?
AveXis headquarters is located at 200 2275 Half Day Rd, Bannockburn.
Where are AveXis offices?
AveXis has an office in Bannockburn.
How many offices does AveXis have?
AveXis has 2 offices.